Merck & Company Inc (MRK)vsWarby Parker Inc (WRBY)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
WRBY
Warby Parker Inc
$22.53
-3.10%
HEALTHCARE · Cap: $2.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7356% more annual revenue ($65.01B vs $871.90M). MRK leads profitability with a 28.1% profit margin vs 0.2%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
WRBY
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+30.9%
Fair Value
$31.81
Current Price
$22.53
$9.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
ROE of 0.5% — below average capital efficiency
0.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : WRBY
Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Return on Equity, Profit Margin. A P/E of 2147.0x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
WRBY carries more volatility with a beta of 2.08 — expect wider price swings.
WRBY is growing revenue faster at 11.2% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 34/100), backed by strong 28.1% margins. WRBY offers better value entry with a 30.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is a pioneering force in the direct-to-consumer eyewear sector, established in 2010 to transform the optical experience through a combination of online convenience and an expanding network of retail locations. The company emphasizes stylish, affordable prescription eyewear and sunglasses, uniquely positioning itself to attract a diverse customer base. Its socially responsible business model, highlighted by the "Buy a Pair, Give a Pair" initiative, underscores a commitment to community welfare, providing eyewear to those in need. With a strong brand identity and innovative marketing approaches, Warby Parker is poised for sustained growth and resilience in an increasingly competitive industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?